Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.
Document type:
Meeting Abstract
Author(s):
Litton, Jennifer Keating; Ettl, Johannes; Hurvitz, Sara A.; Martin, Miguel; Roche, Henri; Lee, Kyung-Hun; Goodwin, Annabel; Usari, Tiziana; Lanzalone, Silvana; Guenzel, Carolin; Blum, Joanne Lorraine; Rugo, Hope S.